Peptides and Peptide Analogues Targeting Acetylcholinesterase-Associated Mechanisms in Alzheimer’s Disease and Dementias: Evidence Gaps, Design Strategies, and Translational Perspectives
- 1Department of Biochemistry and Pharmacogenomics, Medical University of Warsaw, 1 Banacha Str., 02-097 Warsaw, Poland
Abstract
Alzheimer’s disease and related dementias involve interacting disturbances in amyloid-β, tau, neuroinflammation, oxidative stress, mitochondrial function, synaptic integrity, and cholinergic neurotransmission. Acetylcholinesterase, in addition to terminating cholinergic signalling through acetylcholine hydrolysis, participates in non-catalytic interactions associated with amyloid-β, providing a mechanistic rationale for multi-target therapeutic strategies. This critical narrative review evaluates natural acetylcholinesterase-inhibitory peptides, amyloid-targeting sequences, D-enantiomeric and retro-inverso analogues, endogenous and neuroprotective peptides, and selected peptidomimetic and multifunctional designs. The literature is considered according to an evidence hierarchy that distinguishes direct acetylcholinesterase/peripheral anionic site target engagement from independently demonstrated secondary mechanisms, cellular activity, central nervous system exposure, in vivo pharmacodynamics, and clinical efficacy. The reviewed evidence indicates that peptides and peptide-derived compounds offer substantial molecular recognition and structural adaptability and may, in principle, be engineered to combine selected cholinergic and disease-relevant functions. Importantly, no single candidate reviewed here has experimentally demonstrated all of the proposed cholinergic, anti-amyloid, anti-inflammatory, antioxidant, mitochondrial, and synaptoprotective activities simultaneously. However, neuroprotective, anti-amyloid, or cognitive effects alone do not establish direct acetylcholinesterase modulation, and many proposed multifunctional candidates lack experimental evidence of acetylcholinesterase/peripheral anionic site engagement. Overall, the available literature supports the feasibility of designing multifunctional peptide-based acetylcholinesterase-directed agents, but the evidence remains insufficient to establish a clinically validated class of multifunctional acetylcholinesterase modulators.
Related
- Targeting the NLRP3 inflammasome in rheumatoid arthritis fibroblast-like synoviocytes: pathogenic mechanisms, therapeutic strategies, and translational perspectives
- Hydrogel-based delivery of extracellular vesicles for skin wound healing: design strategies, therapeutic mechanisms, and translational perspectives
- Inflammation and wound healing: a comprehensive overview of mechanisms, therapeutic strategies, and translational perspectives
- Low-energy extracorporeal shock wave therapy for interstitial cystitis/bladder pain syndrome: mechanisms, evidence, and translational perspectives—a narrative review
- Osteoimmunology and bone microenvironment remodeling in osteoporosis: mechanisms and translational perspectives
BibTeX
@article{zdunek2026peptides,
title = {{Peptides and Peptide Analogues Targeting Acetylcholinesterase-Associated Mechanisms in Alzheimer’s Disease and Dementias: Evidence Gaps, Design Strategies, and Translational Perspectives}},
author = {Joanna Zdunek and Błażej Grodner},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27209094},
url = {https://www.mdpi.com/1422-0067/27/20/9094},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Peptides and Peptide Analogues Targeting Acetylcholinesterase-Associated Mechanisms in Alzheimer’s Disease and Dementias: Evidence Gaps, Design Strategies, and Translational Perspectives
AU - Joanna Zdunek
AU - Błażej Grodner
PY - 2026
DA - 2026/10/14
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27209094
UR - https://www.mdpi.com/1422-0067/27/20/9094
AB - Alzheimer’s disease and related dementias involve interacting disturbances in amyloid-β, tau, neuroinflammation, oxidative stress, mitochondrial function, synaptic integrity, and cholinergic neurotransmission. Acetylcholinesterase, in addition to terminating cholinergic signalling through acetylcholine hydrolysis, participates in non-catalytic interactions associated with amyloid-β, providing a mechanistic rationale for multi-target therapeutic strategies. This critical narrative review evaluates natural acetylcholinesterase-inhibitory peptides, amyloid-targeting sequences, D-enantiomeric and retro-inverso analogues, endogenous and neuroprotective peptides, and selected peptidomimetic and multifunctional designs. The literature is considered according to an evidence hierarchy that distinguishes direct acetylcholinesterase/peripheral anionic site target engagement from independently demonstrated secondary mechanisms, cellular activity, central nervous system exposure, in vivo pharmacodynamics, and clinical efficacy. The reviewed evidence indicates that peptides and peptide-derived compounds offer substantial molecular recognition and structural adaptability and may, in principle, be engineered to combine selected cholinergic and disease-relevant functions. Importantly, no single candidate reviewed here has experimentally demonstrated all of the proposed cholinergic, anti-amyloid, anti-inflammatory, antioxidant, mitochondrial, and synaptoprotective activities simultaneously. However, neuroprotective, anti-amyloid, or cognitive effects alone do not establish direct acetylcholinesterase modulation, and many proposed multifunctional candidates lack experimental evidence of acetylcholinesterase/peripheral anionic site engagement. Overall, the available literature supports the feasibility of designing multifunctional peptide-based acetylcholinesterase-directed agents, but the evidence remains insufficient to establish a clinically validated class of multifunctional acetylcholinesterase modulators.
SN - 1422-0067
ER -